BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
Globe Newswire•01/09/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.